LSHTM expert comments on NICE approval of first long-acting injectable HIV treatment

NewsGuard 100/100 Score

NHS watch-dog, the National Institute for Health and Care Excellence (NICE), has published guidance recommending the use of the first long-acting injectable treatment for HIV-1. The recommendation of cabotegravir with rilpivirine could provide another treatment option for adults with HIV-1 whose current antiretroviral medicines have kept the virus at a low level and there is no suspected viral resistance and no previous failure of other anti-HIV-1 medicines.

Reacting to the news, Professor Alison Grant, Dean of the Faculty of Infectious and Tropical Diseases at the London School of Hygiene & Tropical Medicine, said: "This approval is very exciting, and has the potential to improve access to life-changing treatment for many. Millions of people living with HIV worldwide live normal, healthy lives thanks to modern antiretroviral treatment, usually taking one or a few tablets once a day. It is great news that this will be another option in the range of antiretroviral treatments for people with HIV in the UK, as some people have difficulty taking tablets regularly - perhaps due to challenging circumstances, including the stigma around HIV, or not having secure accommodation and nowhere to store their medication. However, it's important to note that this is a recommendation from NICE, and there is still much to do before clinics can give these injections to patients; this will take at least several months."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies